	2	What is claimed is:
	3	
\	4	Claim 1. A biopolymer marker selected from the group
	5	consisting of sequence ID (K) SPEQQETVLDGNLIIR(Y),
t	6	(K) IQPSGGTNINEALLR(A), (K) FYNQVSTPLLR(N) or at least one
.•	7	analyte thereof useful in indicating at least one
	8	particular disease state.
	9	
	10	Claim, 2. The biopolymer marker of claim 1 wherein
	11	said disease state is predictive of Alzheimers disease.
H G -	12	
7	13 14	Claim 3. A method for evidencing and categorizing at
f	14	least one disease state comprising:
4	15	obtaining a sample from a patient;
- 4.4 din 4	16	conducting mass spectrometric analysis on said
7 4	17	sample;
	18	evidencing and categorizing at least one biopolymer
	19	marker sequence or analyte thereof isolated from said
	20	sample; and,
	21	comparing said at least one isolated biopolymer
	22	marker sequence or analyte thereof to the biopolymer
	23	marker sequence as set forth in claim 1;
	24	wherein correlation of said isolated biopolymer

CLAIMS

1

1	marker and said biopolymer marker sequence as set forth in
2	claim 1 evidences and categorizes said at least one
3	disease state.
4	
5	Claim 4. The method of claim 3, wherein said step
6	of evidencing and categorizing is particularly directed to
7	biopolymer markers or analytes thereof linked to at least
8	one risk of disease development of said patient.
9	
10	Claim 5. The method of claim 3, wherein said step
11	of evidencing and categorizing is particularly directed to
12	biopolymer markers or analytes thereof related to the
13	existence of a particular disease state.
14	
15	Claim 6. The method of claim 3, wherein the sample
16	is an unfractionated body fluid or a tissue sample.
17	\bigwedge
18	
19	Claim 7. The method of claim $\sqrt{3}$, wherein said sample
20	is at least one of the group consisting of blood, blood
21	products, urine, saliva, cerebrospinal fluid, and lymph.
22	
23	Claim 8. The method of claim 3, wherein said mass
24	spectrometric analysis is selected from the group

```
consisting of Surface Enhanced Laser Desorption Ionization
   1
        (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS,
   2
        TOF-TOF, and ESI-Q-TOF or an ION-TRAP.
   3
   5
             Claim 9.
                        The method of claim 3, wherein said
        patient is a human.
   6
   7
             Claim 10. \ A diagnostic assay kit for determining
        the presence of the biopolymer marker or analyte thereof
   9
        of claim 1 comprising:
  10
를
를 11
             at least one biochemical material which is capable of
₫
12
        specifically binding with a biomolecule which includes at
ال<sub>ا</sub>لية
        least said biopolymer marker or analyte thereof, and
  13
4I
             means for determining binding between said
II 14
15
        biochemical material and said biomolecule;
16
W 17
             whereby at least one analysis to determine a presence
        of a marker, analyte thereof, or a biochemical material
        specific thereto, is carried out on a sample.
  18
  19
                        The diagnostic assay kit of claim 10,
  20
             Claim 11.
        wherein said biochemical material or biomolecule is
  21
        immobilized on a solid support.
  22
  23
                         The diagnostic assay kit of claim 10
             Claim 12.
  24
```

1	Micraalia:
2	at least one labeled biochemical material.
3	
4	Claim 13. The diagnostic assay kit of claim 10,
5	wherein said biochemical material is an antibody.
6	
7	Claim 14. The diagnostic assay kit of claim 12,
8	wherein said labeled biochemical material is an antibody
9	
10	
፭ 11 ጠ	wherein the sample is an unfractionated body fluid or a
12 ≟	tissue sample.
□ 11 □ 12 □ 12 □ 13 □ 14	
1 14	Claim 16. The diagnostic assay kit of claim 10,
≐ 15 ≟	wherein said sample is at least one of the group
U 16 U 17 ⊒ 17	consisting of blood, blood products, urine, saliva,
⊒ 17 ≟	cerebrospinal fluid, and lymph.
18	
19	Claim 17. The diagnostic assay kit of claim 10,
20	
21	
22	
23	<i>y y y</i>
24	assessment, and identifying therapeutic avenues related t

```
à disease state comprising:
   1
   2
             at least one biochemical material which is capable of
   3
        specifically binding with a biomolecule which includes at
   4
        least one biopolymer marker selected from the group
   5
        consisting of sequence ID (K) SPEQQETVLDGNLIIR(Y),
   6
        (K) IQPSGGTNINEALLR(A), (K) FYNQVSTPLLR(N) or at least one
   7
        analyte thereof related to said disease state; and
   8
             means for determining binding between said
        biochemical material and said biomolecule;
   9
  10
             whereby at least one analysis to determine a presence
를
를 11
        of a marker, analyte\ thereof, or a biochemical material
回
回
12
当
13
        specific thereto, is carried out on a sample.
₫
U14
                        The kit of claim 18, wherein said
             Claim 19.
biochemical material or biomolecule is immobilized on a
16
        solid support.
  17
                        The kit of claim 18 including:
  18
             Claim 20.
  19
             at least one labeled biochemical material.
  20
                         The kit of claim 18,\wherein said
  21
             Claim 21.
  22
        biochemical material is an antibody.
  23
  24
                         The kit of claim 20, wherein said labeled
             Claim 22.
```

ű
I
<u>ļ</u>
ű
U
≘
ļ.
ᆣ
N
Ш
ļ-b

1	biochemical material is an antibody.
2	
3	claim 23. The kit of claim 18, wherein the sample is
4	an unfractionated body fluid or a tissue sample.
5	
6	Claim 24 . The kit of claim 18, wherein said sample
7	is at least one of the group consisting of blood, blood
. 8	products, urine, saliva, cerebrospinal fluid, and lymph.
9	
10	Claim 25. The kit of claim 18, wherein said
11	biochemical material is at least one monoclonal antibody
12	specific therefore.
13	
14	Claim 26. The kit of claim 18, wherein said
15	diagnosing, determining risk assessment, and identifying
16	therapeutic avenues is carried out on a single sample.
17	
18	Claim 27. The kit of claim 18, wherein said
19	diagnosing, determining risk assessment, and identifying
20	therapeutic avenues is carried out on multiple samples
21	such that at least one analysis is carried out on a first
22	sample and at least another analysis is carried out on a
23	second sample.
24	
	1

	3	
	4	Claim 29. Polyclonal antibodies produced against a
	5	marker sequence ID selected from the group consisting of
	6	sequence ID (K)SPEQQETVLDGNLIIR(Y), (K)IQPSGGTNINEALLR(A),
	7	(K) FYNQVSTPLLR (N) or at least one analyte thereof in at
	8	least one animal host.
	9	
←	10	Claim 30. An antibody that specifically binds a
	11	biopolymer including a marker selected from the group
I	12	consisting of sequence ID (K)SPEQQETVLDGNLIIR(Y),
	13	(K) IQPSGGTNINEALLR(A), \backslash (K) FYNQVSTPLLR(N) or at least one
	14	analyte thereof.
	15	
	16	Claim 31. The antibody of claim 30 that is a
ļ.	17	monoclonal antibody.
	18	
	19	Claim 32. The antibody of claim 30 that is a
	20	polyclonal antibody.
	21	
	22	Claim 33. A process for identifying therapeutic
	23	avenues related to a disease state comprising:
	24	conducting an analysis as provided by the kit of

Claim 28. The kit of claim 27, wherein said first

and second samples are obtained at different time periods.

1

2

24

claim 18; and 1 2 interacting with a biopolymer selected from the group 3 consisting of sequence ID (K) SPEQQETVLDGNLIIR(Y), 4 (K) IQRSGGTNINEALLR(A), (K) FYNQVSTPLLR(N) or at least one 5 analyte\thereof; whereby therapeutic avenues are developed. 6 7 8 Claim 34. The process for identifying therapeutic 9 avenues related to a disease state in accordance with 10 claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the ₫ 12 group consisting of sequence ID (K) SPEQQETVLDGNLIIR(Y), (K) IQPSGGTNINEALLR(\overrightarrow{A}), (K) FYNQVSTPLLR(\overrightarrow{N}) or at least one 13 analyte thereof. 15 The process for identifying therapeutic 16 Claim 35. avenues related to a disease state in accordance with 17 18 claim 33, wherein said therapeutic avenues developed 19 include at least one avenue selected from a group consisting of 1)utilization and recognition of said 20 biopolymer markers, variants or molieties thereof as direct 21 therapeutic modalities, either alone or in conjunction 22 23 with an effective amount of a pharmaceutically effective

carrier; 2) validation of therapeutic modalities or disease

s
П
₽
H
1
Ü
υĺ
- T
2

1	preventative agents as a function of biopolymer marker
2	presence or concentration; 3) treatment or prevention of a
3	disease state by formation of disease intervention
4	modalities; 4) use of biopolymer markers or moieties
5	thereof\as a means of elucidating therapeutically viable
6	agents, 5 instigation of a therapeutic immunological
7	response; and 6) synthesis of molecular structures related
8	to said biopolymer markers, moieties or variants thereof
9	which are constructed and arranged to therapeutically
0	intervene in said disease state.
1	

Claim 36. The process for identifying therapeutic avenues related to a disease state in accordance with claim 35, wherein said treatment or prevention of a disease state by formation of disease intervention modalities is the formation of biopolymer/ligand conjugates which intervene at receptor sites to prevent, delay or reverse a disease process.

Claim 37. The process for identifying therapeutic avenues related to a disease state in accordance with claim 35, wherein said means of elucidating therapeutically viable agents includes use of a bacteriophage peptide display library or a bacteriophage

	·
1	antibody library.
2	
3	Claim 38. A process for regulating a disease state
4	by control ting the presence or absence of a biopolymer
5	selected from the group consisting of sequence ID
6	(K) SPEQQETVLDGNLIIR(Y), (K) IQPSGGTNINEALLR(A),
7	(K) $FYNQVSTPLLR$ (N) or at least one analyte thereof.
8	
9	
()	